quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

Goldman or Citigroup: Which Transformation Story Is More Compelling?

View original at finance.yahoo.com
Goldman or Citigroup: Which Transformation Story Is More Compelling? Wall Street’s largest institutions are redefining what sustainable growth looks like…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Citigroup is primarily in repair mode with near-term story revolving around cost cuts, divestitures and capital redeployment rather than organic competitive expansion

    80% confidence
  • For investors seeking combination of earnings durability, strategic clarity and long-term upside, GS emerges as more compelling transformation story and stronger stock to own

    80% confidence
  • Asset Management unit intends to expand private credit portfolio to $300 billion by 2029

    80% confidence
  • Management continues to target return on tangible common equity of 10-11% in 2026

    80% confidence
  • Goldman is targeting high-teens returns for the AWM division and roughly 5% annual growth in long-term fee-based net inflows over the medium term

    80% confidence
  • Citigroup expects revenues to see compounded annual growth rate of 4-5% by 2026-end and will drive $2-2.5 billion of annualized run rate savings

    80% confidence
  • Goldman offers clearer growth narrative backed by strengthening fundamentals, upward earnings revisions and strategic focus on high-margin, scalable businesses

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Goldman or Citigroup: Which Transformation Story Is More Compelling? — Source | Via News | pt.VIA.NEWS